Advertisement
Singapore markets closed

  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     

  • Nikkei

    40,912.37
    -1.28 (-0.00%)
     

  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     

  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     

  • Bitcoin USD

    57,234.96
    +751.88 (+1.33%)
     

  • CMC Crypto 200

    1,184.66
    -24.03 (-1.99%)
     

  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     

  • Dow

    39,375.87
    +67.87 (+0.17%)
     

  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     

  • Gold

    2,399.80
    +30.40 (+1.28%)
     

  • Crude Oil

    83.44
    -0.44 (-0.52%)
     

  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,253.37
    +32.48 (+0.45%)
     

  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

Arbitration Dispute Between Daiichi Sankyo and Seagen Ends

Business Wire
·2-min read

  • Daiichi Sankyo received approximately U.S. $47 million from Seagen as awarded by the arbitrator for attorneys’ fees and costs plus interest

TOKYO & BASKING RIDGE, N.J., June 28, 2024--(BUSINESS WIRE)--A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.

Arbitration History and the Award
In August of 2022, an arbitrator issued a decision in a dispute between Daiichi Sankyo and Seagen denying all claims made by Seagen and confirming that Daiichi Sankyo should retain all rights, including patents to its antibody drug conjugate (ADC) technology. In November of 2023, the arbitrator awarded Daiichi Sankyo approximately U.S. $45.5 million in attorneys’ fees and costs.

Seagen subsequently brought an action in federal court to vacate that arbitration award. On April 1, 2024, the federal court denied Seagen’s petition to vacate and awarded Daiichi Sankyo pre- and post-judgment interest on the attorneys’ fees and costs. The deadline to appeal the decision of the federal court in favor of Daiichi Sankyo passed without any filing of an appeal from Seagen.

ADVERTISEMENT

About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240628474403/en/

Contacts

Media Contacts:

Global/Japan:
Daiichi Sankyo Co., Ltd.
DS-PR@daiichisankyo.co.jp

US:
Kim Wix
Daiichi Sankyo, Inc.
kim.wix@daiichisankyo.com
+1 973 992-6633 (o)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp